Moleculin Biotech, Inc. Derivative Liability, Fair Value, Gross Liability
Moleculin Biotech, Inc. (MBRX) had Derivative Liability, Fair Value, Gross Liability of $9.05 million as of 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2020-11-12
- 2020-09-30: Derivative Liability, Fair Value, Gross Liability $9.05M.
- 2019-12-31: Derivative Liability, Fair Value, Gross Liability $5.82M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2020-09-30 | $9.05M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $5.82M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |